19X Stock Overview
A biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Axsome Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$71.36 |
| 52 Week High | US$91.90 |
| 52 Week Low | US$52.42 |
| Beta | 1.25 |
| 11 Month Change | 5.66% |
| 3 Month Change | 8.35% |
| 1 Year Change | 9.01% |
| 33 Year Change | 34.85% |
| 5 Year Change | 212.98% |
| Change since IPO | 1,853.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 19X | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.3% | -1.7% | 0.6% |
| 1Y | 9.0% | -19.9% | 3.3% |
Return vs Industry: 19X exceeded the German Pharmaceuticals industry which returned -19.9% over the past year.
Return vs Market: 19X exceeded the German Market which returned 3.3% over the past year.
Price Volatility
| 19X volatility | |
|---|---|
| 19X Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 19X has not had significant price volatility in the past 3 months.
Volatility Over Time: 19X's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 569 | Herriot Tabuteau | www.axsome.com |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder.
Axsome Therapeutics, Inc. Fundamentals Summary
| 19X fundamental statistics | |
|---|---|
| Market cap | €3.53b |
| Earnings (TTM) | -€274.42m |
| Revenue (TTM) | €232.42m |
15.2x
P/S Ratio-12.9x
P/E RatioIs 19X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 19X income statement (TTM) | |
|---|---|
| Revenue | US$251.02m |
| Cost of Revenue | US$24.81m |
| Gross Profit | US$226.22m |
| Other Expenses | US$522.59m |
| Earnings | -US$296.38m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.24 |
| Gross Margin | 90.12% |
| Net Profit Margin | -118.07% |
| Debt/Equity Ratio | 124.1% |
How did 19X perform over the long term?
See historical performance and comparison